carvedilol has been researched along with Cardiomyopathies in 45 studies
Cardiomyopathies: A group of diseases in which the dominant feature is the involvement of the CARDIAC MUSCLE itself. Cardiomyopathies are classified according to their predominant pathophysiological features (DILATED CARDIOMYOPATHY; HYPERTROPHIC CARDIOMYOPATHY; RESTRICTIVE CARDIOMYOPATHY) or their etiological/pathological factors (CARDIOMYOPATHY, ALCOHOLIC; ENDOCARDIAL FIBROELASTOSIS).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Relative effectiveness of carvedilol and metoprolol succinate has never been compared in patients with heart failure (HF)." | 7.78 | Carvedilol or sustained-release metoprolol for congestive heart failure: a comparative effectiveness analysis. ( Aggarwal, V; Shore, S; Zolty, R, 2012) |
| "Carvedilol therapy reduces mortality from sudden cardiac death and progressive pump failure in congestive heart failure (CHF)." | 7.71 | The effects of chronic carvedilol therapy on QT dispersion in patients with congestive heart failure. ( Oto, A; Sade, E; Tokgozoglu, L; Yildirir, A, 2001) |
| "Carvedilol is a non-selective beta-blocker with alpha-receptor blockade and antioxidant properties." | 5.32 | Chronic treatment with carvedilol improves ventricular function and reduces myocyte apoptosis in an animal model of heart failure. ( Doye, AA; Gwathmey, JK; Hajjar, RJ; Jabbour, G; Laste, N; Lebeche, D; Lee, MX; Okafor, CC; Perreault-Micale, C; Skiroman, K, 2003) |
| "Herein two breast cancer cell lines, SKBr3 and BT474, overexpressing human epithelial receptor 2 (HER2), the target of the humanised antibody trastuzumab, were treated with a range of concentrations (20-2000 nM) of doxorubicin with and without trastuzumab in the presence of clinically relevant doses of the ACE inhibitor enalapril, the beta-blocker carvedilol, metformin or dexrazoxane, and cell survival determined using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay." | 3.83 | Effects of Administered Cardioprotective Drugs on Treatment Response of Breast Cancer Cells. ( Akabuogu, EU; Phyu, SM; Smith, TA, 2016) |
| "Relative effectiveness of carvedilol and metoprolol succinate has never been compared in patients with heart failure (HF)." | 3.78 | Carvedilol or sustained-release metoprolol for congestive heart failure: a comparative effectiveness analysis. ( Aggarwal, V; Shore, S; Zolty, R, 2012) |
| " In this report, we describe 5 cases of severe chronic heart failure due to ACM effectively treated with the beta-blocker, carvedilol." | 3.72 | Five cases of anthracycline-induced cardiomyopathy effectively treated with carvedilol. ( Iwato, K; Kaseda, S; Kyo, T; Mukai, N; Mukai, Y; Nakaike, R; Yoshida, T, 2004) |
| "Carvedilol therapy reduces mortality from sudden cardiac death and progressive pump failure in congestive heart failure (CHF)." | 3.71 | The effects of chronic carvedilol therapy on QT dispersion in patients with congestive heart failure. ( Oto, A; Sade, E; Tokgozoglu, L; Yildirir, A, 2001) |
| "Carvedilol has established its evidence to improve prognosis and facilitate left ventricular reverse remodeling (LVRR) in heart failure patients with reduced left ventricular ejection fraction (LVEF), and many studies have supported its dose-dependency." | 2.82 | High Dose β-Blocker Therapy Triggers Additional Reverse Remodeling in Patients With Idiopathic Non-Ischemic Cardiomyopathy. ( Imamura, T; Kato, NP; Kinugawa, K; Komuro, I; Nitta, D, 2016) |
| " The two referred examples result in important take-home messages: a) drug-induced cardiac mitochondrial dysfunction is an important contributor for drug-associated organ failure, b) protection of mitochondrial function is involved in the beneficial impact of some clinically-used drugs and c) a more accurate prediction of toxic vs." | 2.47 | Drug-induced cardiac mitochondrial toxicity and protection: from doxorubicin to carvedilol. ( Carvalho, FS; Diogo, CV; Monteiro, P; Oliveira, PJ; Pereira, GC; Silva, AM, 2011) |
| " To tackle this issue, we established embryonic zebrafish models of doxorubicin-, adrenaline- and terfenadine-induced cardiotoxicity with unified dosing regimen which eventually enabled head-to-head comparison of the drugs." | 1.72 | Pharmacological assessment of zebrafish-based cardiotoxicity models. ( Maciag, M; Mierzejewska, M; Plazinska, A; Wnorowski, A, 2022) |
| "However, she experienced recurrence with positive T790 M, and osimertinib (80 mg/day) was administered as the 2nd line therapy." | 1.56 | Osimertinib induced cardiomyopathy: A case report. ( Ishikawa, K; Kagamu, H; Kaira, K; Shinomiya, S; Yamaguchi, O, 2020) |
| "We here report a HF patient with left bundle branch block due to nonischemic cardiomyopathy who did not respond to 20 mg/day of carvedilol in terms of LVRR." | 1.42 | Reverse Remodeling Achieved by Combination Therapy With High-Dose Beta Blocker and Cardiac Resynchronization. ( Imamura, T; Kinugawa, K; Muraoka, H, 2015) |
| "Carvedilol is a non-selective beta-blocker with alpha-receptor blockade and antioxidant properties." | 1.32 | Chronic treatment with carvedilol improves ventricular function and reduces myocyte apoptosis in an animal model of heart failure. ( Doye, AA; Gwathmey, JK; Hajjar, RJ; Jabbour, G; Laste, N; Lebeche, D; Lee, MX; Okafor, CC; Perreault-Micale, C; Skiroman, K, 2003) |
| "Patients with Becker muscular dystrophy-related cardiomyopathy typically survive into their 30s, when they succumb to complications of cardiomyopathy or receive heart transplants." | 1.31 | Becker muscular dystrophy-related cardiomyopathy: a favorable response to medical therapy. ( Doing, AH; Renlund, DG; Smith, RA, 2002) |
| "Carvedilol (CAR) is a vasodilating beta-blocker which also has antioxidant properties." | 1.30 | Protective effects of carvedilol against doxorubicin-induced cardiomyopathy in rats. ( Hayakawa, T; Matsui, H; Morishima, I; Numaguchi, Y; Okumura, K; Toki, Y, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (2.22) | 18.7374 |
| 1990's | 1 (2.22) | 18.2507 |
| 2000's | 21 (46.67) | 29.6817 |
| 2010's | 16 (35.56) | 24.3611 |
| 2020's | 6 (13.33) | 2.80 |
| Authors | Studies |
|---|---|
| Maciag, M | 1 |
| Wnorowski, A | 1 |
| Mierzejewska, M | 1 |
| Plazinska, A | 1 |
| Imamura, T | 3 |
| Izumida, T | 1 |
| Hori, M | 1 |
| Tanaka, S | 1 |
| Kinugawa, K | 3 |
| Kadoya, T | 1 |
| Sakakibara, A | 1 |
| Kitayama, K | 1 |
| Yamada, Y | 1 |
| Higuchi, S | 1 |
| Kawakita, R | 1 |
| Kawasaki, Y | 1 |
| Fujino, M | 1 |
| Murakami, Y | 1 |
| Shimura, M | 1 |
| Murayama, K | 1 |
| Ohtake, A | 1 |
| Okazaki, Y | 1 |
| Koga, Y | 1 |
| Yorifuji, T | 1 |
| Alanazi, A | 1 |
| Fadda, L | 1 |
| Alhusaini, A | 1 |
| Ahmad, R | 1 |
| Syed, MP | 1 |
| Doshi, A | 1 |
| Pandey, D | 1 |
| Kate, Y | 1 |
| Harizi, R | 1 |
| Beiranvand, E | 1 |
| Torkashvand, F | 1 |
| Ostad, SN | 1 |
| Mirzaie, M | 1 |
| Ardakani, EM | 1 |
| Zandi, F | 1 |
| Sardari, S | 1 |
| Salekdeh, GH | 1 |
| Shokrgozar, MA | 1 |
| Vaziri, B | 1 |
| Shinomiya, S | 1 |
| Kaira, K | 1 |
| Yamaguchi, O | 1 |
| Ishikawa, K | 1 |
| Kagamu, H | 1 |
| Jhorawat, R | 1 |
| Kumari, S | 1 |
| Varma, SC | 1 |
| Rohit, MK | 1 |
| Narula, N | 1 |
| Suri, V | 1 |
| Malhotra, P | 1 |
| Jain, S | 1 |
| Kida, K | 1 |
| Yoneyama, K | 1 |
| Kobayashi, Y | 1 |
| Takano, M | 1 |
| Akashi, YJ | 1 |
| Miyake, F | 1 |
| Abu-Elsaad, NM | 1 |
| Abd Elhameed, AG | 1 |
| El-Karef, A | 1 |
| Ibrahim, TM | 1 |
| Muraoka, H | 1 |
| Teoh, JP | 1 |
| Park, KM | 1 |
| Broskova, Z | 1 |
| Jimenez, FR | 1 |
| Bayoumi, AS | 1 |
| Archer, K | 1 |
| Su, H | 1 |
| Johnson, J | 1 |
| Weintraub, NL | 1 |
| Tang, Y | 1 |
| Kim, IM | 1 |
| Chen, YL | 2 |
| Chung, SY | 1 |
| Chai, HT | 1 |
| Chen, CH | 1 |
| Liu, CF | 1 |
| Huang, TH | 1 |
| Zhen, YY | 1 |
| Sung, PH | 1 |
| Sun, CK | 1 |
| Chua, S | 1 |
| Lu, HI | 1 |
| Lee, FY | 1 |
| Sheu, JJ | 1 |
| Yip, HK | 1 |
| Smith, TA | 1 |
| Phyu, SM | 1 |
| Akabuogu, EU | 1 |
| Nitta, D | 1 |
| Kato, NP | 1 |
| Komuro, I | 2 |
| Wang, K | 1 |
| Lu, D | 1 |
| Zhang, B | 1 |
| Wang, S | 1 |
| Liu, Q | 1 |
| Zhang, Q | 1 |
| Geng, J | 1 |
| Shan, Q | 1 |
| de Groote, P | 1 |
| Lamblin, N | 1 |
| Mouquet, F | 1 |
| Bauters, C | 1 |
| Auerbach, SR | 1 |
| Richmond, ME | 1 |
| Lamour, JM | 1 |
| Blume, ED | 1 |
| Addonizio, LJ | 1 |
| Shaddy, RE | 1 |
| Mahony, L | 1 |
| Pahl, E | 1 |
| Hsu, DT | 1 |
| Mah, D | 1 |
| Wang, A | 1 |
| Wu, A | 1 |
| Alexander, ME | 1 |
| Walsh, EP | 1 |
| Pereira, GC | 1 |
| Silva, AM | 1 |
| Diogo, CV | 1 |
| Carvalho, FS | 1 |
| Monteiro, P | 2 |
| Oliveira, PJ | 3 |
| He, L | 1 |
| Xiao, J | 1 |
| Fu, H | 1 |
| Du, G | 1 |
| Xiao, X | 1 |
| Zhang, C | 1 |
| Gu, Y | 1 |
| Ma, Y | 1 |
| Elnakish, MT | 1 |
| Hassona, MD | 1 |
| Alhaj, MA | 1 |
| Moldovan, L | 1 |
| Janssen, PM | 1 |
| Khan, M | 1 |
| Hassanain, HH | 1 |
| Shore, S | 1 |
| Aggarwal, V | 1 |
| Zolty, R | 1 |
| Takano, H | 1 |
| Harada, T | 1 |
| Ohtaki, E | 2 |
| Kitahara, K | 2 |
| Sumiyoshi, T | 2 |
| Hosoda, S | 2 |
| Santos, DL | 1 |
| Moreno, AJ | 3 |
| Leino, RL | 2 |
| Froberg, MK | 2 |
| Wallace, KB | 2 |
| Takeda, N | 1 |
| Misu, K | 1 |
| Asano, R | 1 |
| Tobaru, T | 1 |
| Nagayama, M | 1 |
| Umemura, J | 1 |
| Okafor, CC | 1 |
| Perreault-Micale, C | 1 |
| Hajjar, RJ | 1 |
| Lebeche, D | 1 |
| Skiroman, K | 1 |
| Jabbour, G | 1 |
| Doye, AA | 1 |
| Lee, MX | 1 |
| Laste, N | 1 |
| Gwathmey, JK | 1 |
| Armstrong, SC | 1 |
| Bjork, JA | 1 |
| Santos, MS | 1 |
| Mukai, Y | 1 |
| Yoshida, T | 1 |
| Nakaike, R | 1 |
| Mukai, N | 1 |
| Iwato, K | 1 |
| Kyo, T | 1 |
| Kaseda, S | 1 |
| Meyers, DE | 1 |
| Maddicks-Law, J | 1 |
| Seaton, DM | 1 |
| Galbraith, AJ | 1 |
| Cuneo, RC | 1 |
| Gonçalves, L | 1 |
| Providencia, LA | 1 |
| Bozić, I | 1 |
| Fabijanić, D | 1 |
| Carević, V | 1 |
| Polić, S | 1 |
| Kalay, N | 1 |
| Basar, E | 1 |
| Ozdogru, I | 1 |
| Er, O | 1 |
| Cetinkaya, Y | 1 |
| Dogan, A | 1 |
| Inanc, T | 1 |
| Oguzhan, A | 1 |
| Eryol, NK | 1 |
| Topsakal, R | 1 |
| Ergin, A | 1 |
| Florenzano, F | 1 |
| Salman, P | 1 |
| Cruz, N | 1 |
| Arocho, L | 1 |
| Rosario, L | 1 |
| Crespo, MJ | 1 |
| Nakanishi, M | 1 |
| Harada, M | 1 |
| Tadamura, E | 1 |
| Kotani, H | 1 |
| Kawakami, R | 1 |
| Kuwahara, K | 1 |
| Nakagawa, Y | 1 |
| Usami, S | 1 |
| Kinoshita, H | 1 |
| Fujiwara, M | 1 |
| Hosoda, K | 1 |
| Ueshima, K | 1 |
| Nakao, K | 1 |
| Matsui, H | 1 |
| Morishima, I | 1 |
| Numaguchi, Y | 1 |
| Toki, Y | 1 |
| Okumura, K | 1 |
| Hayakawa, T | 1 |
| Noori, A | 1 |
| Lindenfeld, J | 1 |
| Wolfel, E | 1 |
| Ferguson, D | 1 |
| Bristow, MR | 1 |
| Lowes, BD | 1 |
| Witte, K | 1 |
| Thackray, S | 1 |
| Clark, AL | 1 |
| Cooklin, M | 1 |
| Cleland, JG | 1 |
| Yildirir, A | 1 |
| Sade, E | 1 |
| Tokgozoglu, L | 1 |
| Oto, A | 1 |
| Doing, AH | 1 |
| Renlund, DG | 1 |
| Smith, RA | 1 |
| Kaski, JC | 1 |
| Rodriguez-Plaza, L | 1 |
| Brown, J | 1 |
| Maseri, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of Spironolactone in the Prevention of Anthracycline-induced Cardiotoxicity: a Randomized Clinical Trial (SPIROTOX Trial)[NCT06005259] | Phase 4 | 264 participants (Anticipated) | Interventional | 2023-10-01 | Not yet recruiting | ||
| Evaluation of Empagliflozin Effect Against Doxorubicin Induced Cardiomyopathy[NCT06103279] | Phase 2/Phase 3 | 40 participants (Anticipated) | Interventional | 2023-11-30 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for carvedilol and Cardiomyopathies
| Article | Year |
|---|---|
Drug-induced cardiac mitochondrial toxicity and protection: from doxorubicin to carvedilol.
Topics: Adrenergic beta-Antagonists; Antibiotics, Antineoplastic; Carbazoles; Cardiomyopathies; Cardiotonic | 2011 |
Are the antioxidant properties of carvedilol important for the protection of cardiac mitochondria?
Topics: Adrenergic beta-Antagonists; Animals; Antioxidants; Carbazoles; Cardiomyopathies; Carvedilol; Humans | 2005 |
Echocardiography in the diagnosis and management of isolated left ventricular noncompaction: case reports and review of the literature.
Topics: Anticoagulants; Carbazoles; Cardiomyopathies; Carvedilol; Diagnosis, Differential; Echocardiography; | 2006 |
4 trials available for carvedilol and Cardiomyopathies
| Article | Year |
|---|---|
High Dose β-Blocker Therapy Triggers Additional Reverse Remodeling in Patients With Idiopathic Non-Ischemic Cardiomyopathy.
Topics: Adrenergic beta-Antagonists; Adult; Blood Pressure; Carbazoles; Cardiomyopathies; Carvedilol; Dose-R | 2016 |
Protective effects of carvedilol against anthracycline-induced cardiomyopathy.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adult; Anthracyclines; Antibiotics, Antin | 2006 |
Protective effects of carvedilol against anthracycline-induced cardiomyopathy.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adult; Anthracyclines; Antibiotics, Antin | 2006 |
Protective effects of carvedilol against anthracycline-induced cardiomyopathy.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adult; Anthracyclines; Antibiotics, Antin | 2006 |
Protective effects of carvedilol against anthracycline-induced cardiomyopathy.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adult; Anthracyclines; Antibiotics, Antin | 2006 |
[Efficiency of taliton in treatment of ischemic cardiomyopathy].
Topics: Adult; Aged; Antihypertensive Agents; Carbazoles; Cardiomyopathies; Carvedilol; Humans; Male; Middle | 2007 |
Efficacy of carvedilol (BM 14,190), a new beta-blocking drug with vasodilating properties, in exercise-induced ischemia.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Blood Pressure; Carbazoles; Cardiomyopathies; Carvedilol; | 1985 |
38 other studies available for carvedilol and Cardiomyopathies
| Article | Year |
|---|---|
Pharmacological assessment of zebrafish-based cardiotoxicity models.
Topics: Animals; Cardiomyopathies; Cardiotoxicity; Carvedilol; Doxorubicin; Zebrafish | 2022 |
Combination therapy using tafamidis and neurohormonal blockers for cardiac amyloidosis and a reduced ejection fraction: a case report.
Topics: Aged; Amyloidosis; Benzoxazoles; Cardiomyopathies; Carvedilol; Humans; Male; Stroke Volume; Ventricu | 2022 |
Successful treatment of infantile-onset ACAD9-related cardiomyopathy with a combination of sodium pyruvate, beta-blocker, and coenzyme Q10.
Topics: Acidosis; Acyl-CoA Dehydrogenase; Acyl-CoA Dehydrogenases; Adrenergic beta-Antagonists; Amino Acid M | 2019 |
Antioxidant, antiapoptotic, and antifibrotic effects of the combination of liposomal resveratrol and carvedilol against doxorubicin-induced cardiomyopathy in rats.
Topics: Animals; Antibiotics, Antineoplastic; Antioxidants; Apoptosis; Cardiomyopathies; Cardiotoxicity; Car | 2020 |
A rare case of biventricular non-compaction.
Topics: Cardiomyopathies; Carvedilol; Coronary Artery Disease; Dyspnea; Furosemide; Heart Failure; Heart Ven | 2020 |
Proteomics Analysis of Trastuzumab Toxicity in the H9c2 Cardiomyoblast Cell Line and its Inhibition by Carvedilol.
Topics: Adrenergic beta-Antagonists; Antineoplastic Agents, Immunological; Breast Neoplasms; Cardiomyopathie | 2020 |
Osimertinib induced cardiomyopathy: A case report.
Topics: Acrylamides; Adenocarcinoma of Lung; Adrenergic beta-Antagonists; Afatinib; Aged; Angiotensin-Conver | 2020 |
Preventive role of carvedilol in adriamycin-induced cardiomyopathy.
Topics: Aged; Carbazoles; Cardiomyopathies; Carvedilol; Doxorubicin; Echocardiography; Female; Heart Failure | 2016 |
Late gadolinium enhancement on cardiac magnetic resonance images predicts reverse remodeling in patients with nonischemic cardiomyopathy treated with carvedilol.
Topics: Adult; Aged; Carbazoles; Cardiomyopathies; Carvedilol; Female; Gadolinium; Heart Failure; Humans; Ma | 2013 |
Yogurt Containing the Probacteria Lactobacillus acidophilus Combined with Natural Antioxidants Mitigates Doxorubicin-Induced Cardiomyopathy in Rats.
Topics: Angiotensin II; Animals; Antioxidants; Atrial Natriuretic Factor; Camellia sinensis; Carbazoles; Car | 2015 |
Reverse Remodeling Achieved by Combination Therapy With High-Dose Beta Blocker and Cardiac Resynchronization.
Topics: Adrenergic beta-Antagonists; Bundle-Branch Block; Carbazoles; Cardiac Resynchronization Therapy; Car | 2015 |
Identification of gene signatures regulated by carvedilol in mouse heart.
Topics: Adrenergic beta-Antagonists; Animals; Carbazoles; Cardiomyopathies; Carvedilol; Gene Expression Regu | 2015 |
Early Administration of Carvedilol Protected against Doxorubicin-Induced Cardiomyopathy.
Topics: Adrenergic beta-Antagonists; Animals; Antibiotics, Antineoplastic; Biomarkers; Carbazoles; Cardiomyo | 2015 |
Effects of Administered Cardioprotective Drugs on Treatment Response of Breast Cancer Cells.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antineoplastic Combined Chemo | 2016 |
Renal Denervation Attenuates Multi-Organ Fibrosis and Improves Vascular Remodeling in Rats with Transverse Aortic Constriction Induced Cardiomyopathy.
Topics: Alanine Transaminase; Angiotensin II; Animals; Aorta; Blood Pressure; Carbazoles; Cardiomegaly; Card | 2016 |
No gender survival difference in a population of patients with chronic heart failure related to left ventricular systolic dysfunction and receiving optimal medical therapy.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Carbazoles; Cardiomyopathies; | 2008 |
BNP levels predict outcome in pediatric heart failure patients: post hoc analysis of the Pediatric Carvedilol Trial.
Topics: Adrenergic beta-Antagonists; Age Factors; Biomarkers; Carbazoles; Cardiomyopathies; Carvedilol; Chi- | 2010 |
Marked QT prolongation and ventricular tachycardia of a transient nature in young children with cardiomyopathy.
Topics: Carbazoles; Cardiomyopathies; Cardiotonic Agents; Carvedilol; Child; Electrocardiography; Humans; In | 2012 |
Effect of oxidative stress on ventricular arrhythmia in rabbits with adriamycin-induced cardiomyopathy.
Topics: Animals; Anti-Arrhythmia Agents; Antibiotics, Antineoplastic; Carbazoles; Cardiomyopathies; Carvedil | 2012 |
Rac-induced left ventricular dilation in thyroxin-treated ZmRacD transgenic mice: role of cardiomyocyte apoptosis and myocardial fibrosis.
Topics: Animals; Apoptosis; Blotting, Western; Carbazoles; Cardiomegaly; Cardiomyopathies; Carvedilol; Echoc | 2012 |
Carvedilol or sustained-release metoprolol for congestive heart failure: a comparative effectiveness analysis.
Topics: Adrenergic beta-Antagonists; Carbazoles; Cardiomyopathies; Carvedilol; Cohort Studies; Delayed-Actio | 2012 |
Beta-blockers have beneficial effects even on unclassified cardiomyopathy such as isolated ventricular noncompaction.
Topics: Adrenergic beta-Antagonists; Carbazoles; Cardiomyopathies; Carvedilol; Humans; Propanolamines | 2002 |
Carvedilol-induced changes in cardiac diastolic performance in a patient with isolated noncompaction of the myocardium.
Topics: Adrenergic beta-Antagonists; Adult; Carbazoles; Cardiomyopathies; Carvedilol; Diastole; Echocardiogr | 2002 |
Carvedilol protects against doxorubicin-induced mitochondrial cardiomyopathy.
Topics: Adrenergic beta-Antagonists; Algorithms; Animals; Antibiotics, Antineoplastic; Biological Transport; | 2002 |
Normalization of left ventricular parameters following combined pimobendan and carvedilol treatment in a case of unclassified cardiomyopathy with longstanding refractory status.
Topics: Carbazoles; Cardiomyopathies; Cardiovascular Agents; Carvedilol; Heart Failure; Humans; Male; Middle | 2002 |
Chronic treatment with carvedilol improves ventricular function and reduces myocyte apoptosis in an animal model of heart failure.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Animals; Antioxidants; Apoptosis; Carbazo | 2003 |
Anti-oxidants and apoptosis: attenuation of doxorubicin induced cardiomyopathy by carvedilol.
Topics: Animals; Antibiotics, Antineoplastic; Antioxidants; Apoptosis; Carbazoles; Cardiomyopathies; Carvedi | 2004 |
Carvedilol-mediated antioxidant protection against doxorubicin-induced cardiac mitochondrial toxicity.
Topics: Adrenergic beta-Antagonists; Animals; Antibiotics, Antineoplastic; Antioxidants; Calcium; Carbazoles | 2004 |
Five cases of anthracycline-induced cardiomyopathy effectively treated with carvedilol.
Topics: Adrenergic beta-Antagonists; Adult; Anthracyclines; Carbazoles; Cardiomyopathies; Carvedilol; Echoca | 2004 |
The role of growth hormone replacement in a growth hormone deficient patient with underlying cardiomyopathy and severe congestive heart failure.
Topics: Adrenergic beta-Antagonists; Adult; Angiotensin-Converting Enzyme Inhibitors; Biomarkers; Carbazoles | 2005 |
Carvedilol for anthracycline cardiomyopathy prevention.
Topics: Anthracyclines; Carbazoles; Cardiomyopathies; Carvedilol; Dose-Response Relationship, Drug; Humans; | 2007 |
Chronic administration of carvedilol improves cardiac function in 6-month-old Syrian cardiomyopathic hamsters.
Topics: Adrenergic beta-Antagonists; Animals; Blood Pressure; Carbazoles; Cardiac Output; Cardiomyopathies; | 2007 |
Images in cardiovascular medicine. Mitochondrial cardiomyopathy evaluated with cardiac magnetic resonance.
Topics: Aged; Biopsy; Carbazoles; Cardiomyopathies; Carvedilol; Coenzymes; Coronary Angiography; Enalapril; | 2007 |
Protective effects of carvedilol against doxorubicin-induced cardiomyopathy in rats.
Topics: Animals; Antibiotics, Antineoplastic; Antioxidants; Blood Pressure; Carbazoles; Cardiomyopathies; Ca | 1999 |
Beta-blockade in adriamycin-induced cardiomyopathy.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Antineoplastic Agents; Carbazoles; Cardiomyopathies; Cardi | 2000 |
Clinical trials update: IMPROVEMENT-HF, COPERNICUS, MUSTIC, ASPECT-II, APRICOT and HEART.
Topics: Adrenergic beta-Antagonists; Anticoagulants; Carbazoles; Cardiomyopathies; Carvedilol; Clinical Tria | 2000 |
The effects of chronic carvedilol therapy on QT dispersion in patients with congestive heart failure.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Carbazoles; Cardiomyopathies; Carvedilol; Dose-Response Re | 2001 |
Becker muscular dystrophy-related cardiomyopathy: a favorable response to medical therapy.
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Captopril; Carbazoles; Cardiomyopat | 2002 |